ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2140

Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

Linda Laaouad1, Janet Roberts 2, Daniel Ennis 3, Carrie Ye 4, Karam Al Jumaily 5, Marie Hudson 6, Shahin Jamal 7, Janet Pope 8, Tatiana Nevskaya 9, Alexandra Saltman 10, Megan Himmel 11, Aurore Fifi-Mah 12, Annaliese Tisseverasinghe 13, Nancy Maltez 14, Ines Colmegna 15 and Sabrina Hoa 16, 1University of Montreal, Montreal, Canada, 2Dalhousie University, Halifax, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5University of Alberta, Edmonton, Canada, 6Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, 7University of British Columbia, Vancouver, BC, Canada, 8Western University, London, ON, Canada, 9University of Western Ontario, London, ON, Canada, 10University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, 11University of Toronto, Toronto, Canada, 12University of Calgary, Calgary, AB, Canada, 13University of Manitoba, Winnipeg, MB, Canada, 14University of Ottawa, Ottawa, ON, Canada, 15McGill University Health Center, Montreal, QC, Canada, 16University of Montreal, Montreal, QC, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Immunotherapy, Oncology and adverse events, Rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events (irAEs). Limited data is available on the safety of ICIs in patients with preexisting autoimmune diseases and on concomitant use of immunosuppressive drugs. CanRIO is a network of Canadian rheumatologists with experience in the management of rheumatic irAEs secondary to ICIs. In this case series, we describe the clinical course of patients with preexisting autoimmune diseases who were treated with ICIs at 7 CanRIO sites.

Methods: Patients referred for rheumatological evaluation in the context of immunotherapy between 2013 and March 2019 at participating CanRIO sites with preexisting autoimmune disease were identified. Standardized data were extracted by retrospective chart review. Descriptive statistics were used to summarize the data.

Results: A total of 25 patients with preexisting autoimmune disease who received ICI treatment were identified. Their age was 62.9 ± 11.9 (mean ± SD), 13 (52%) were male, and 23 (92%) were White. Mean (SD) follow-up was 13.1 (9.2) months. The most common indications for ICI were advanced lung cancer (n=13, 52%) and melanoma (n=9, 36%); 96% had stage 4 disease. Most patients received ICI monotherapy (Pembrolizumab: n=17, 68%; Nivolumab: n=6, 24%).

Preexisting autoimmune diseases included rheumatoid arthritis (RA, n=8), psoriasis (n=4), psoriatic arthritis (n=3), axial spondyloarthropathy (SpA, n=3), systemic lupus erythematosus (SLE, n=2), dermatomyositis (n=1), polymyalgia rheumatica (PMR, n=1) and other non-rheumatic diseases (n=3).

Of 8 patients with RA, 71% (5/7) were seropositive (RF ±anti-CCP) and 43% (3/7) had erosive disease. 50% (4/8) were in remission at time of ICI initiation, 29% (2/7) had their DMARDs stopped, 29% (2/7) continued their DMARD(s) and 43% (3/7) had new DMARD(s) started prophylactically. Overall, 50% (4/8) experienced grade ≤ 2 flares of their polyarthritis, 13% (1/8) developed PMR de novoand 38% (3/8) did not have any rheumatic irAE. Of those who developed rheumatic irAEs, 80% (4/5) received Nivolumab, 80% (4/5) had seropositive disease, 63% (5/8) were on DMARDs at time of ICI initiation and 80% (4/5) events occurred after a single dose of ICI.

Of 4 patients with psoriasis but without arthritis, 3 (75%) experienced a flare (both mild and major) of their skin disease and 3 (75%) developed de novo arthritis (grade 2-3) within the first 4 months of ICI treatment. Of 3 patients with axial SpA, two experienced new peripheral arthritis (grade 2) after receiving ICI.

Inflammatory arthritis responded to oral corticosteroids (up to 50 mg, tapered over 4-9 months) and/or addition of DMARDs (methotrexate, hydroxychloroquine and/or sulfasalazine), and required ICI discontinuation in 27% (3/11) of patients. Two patients with SLE remained in remission (on hydroxychloroquine).

Conclusion: This is the largest multicentered study of patients with rheumatic autoimmune diseases exposed to immunotherapy. Arthritis flares in patients with RA exposed to ICI are frequent despite DMARD background therapy. New onset of peripheral arthritis is frequent in SpA and psoriatic patients.


Disclosure: L. Laaouad, None; J. Roberts, None; D. Ennis, None; C. Ye, None; K. Al Jumaily, None; M. Hudson, None; S. Jamal, Abbvie, 5, Amgen, 5, BMS, 5, Eli Lilly, 5, Janssen, 5, Merck, 5, Pfizer, 5; J. Pope, AbbVie, 5, Abbvie, 5, Actelion, 5, Actellion, 5, Amgen, 2, 5, AstraZeneca, 2, Astra-Zeneca, 2, Bayer, 2, 5, BMS, 2, 5, Eicos Sciences, 5, Eli Lilly & Company, 5, Eli Lilly and Company, 5, EMERALD, 5, Emerald, 5, Genzyme, 5, Janssen, 5, Lilly, 5, Merck, 2, 5, Novartis, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 5, Sanofi, 5, Seattle Genetics, 2, UCB, 2, 5, 8; T. Nevskaya, None; A. Saltman, None; M. Himmel, None; A. Fifi-Mah, Abbvie, 5, BMS, 5, 8, Celgene, 5, Janssen, 5, 8, Pfizer, 8, Roche, 2, 5, Sanofi, 5; A. Tisseverasinghe, None; N. Maltez, None; I. Colmegna, None; S. Hoa, None.

To cite this abstract in AMA style:

Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K, Hudson M, Jamal S, Pope J, Nevskaya T, Saltman A, Himmel M, Fifi-Mah A, Tisseverasinghe A, Maltez N, Colmegna I, Hoa S. Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/preexisting-autoimmune-disease-and-rheumatic-immune-related-adverse-events-associated-with-cancer-immunotherapy-a-case-series-from-the-canadian-research-group-of-rheumatology-in-immuno-oncology-canr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preexisting-autoimmune-disease-and-rheumatic-immune-related-adverse-events-associated-with-cancer-immunotherapy-a-case-series-from-the-canadian-research-group-of-rheumatology-in-immuno-oncology-canr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology